Announcement of the consolidated financial report for the
2nd quarter of 2022 approved by the board of directors
Date of events
2022/08/03
To which item it meets
paragraph 31
Statement
1.Date of submission to the board of directors or approval by the board of
directors:2022/08/03
2.Date of approval by the audit committee:2022/08/03
3.Start and end dates of financial reports or annual self-assessed financial
information of the reporting period (XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):848609
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):301992
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):125970
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):138192
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):115627
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):115627
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):1.14
11.Total assets end of the period (thousand NTD):3415786
12.Total liabilities end of the period
(thousand NTD):1241730
13.Equity attributable to owners of parent end of the
period (thousand NTD):2174056
14.Any other matters that need to be specified:None.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Nang Kuang Pharmaceutical Co. Ltd. published this content on 03 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2022 10:17:06 UTC.
NANG KUANG PHARMACEUTICAL CO., LTD. is principally engaged in the manufacture, processing and trading of western medicine. The company main products include injections, sterile injections, powder injections, hard capsules, bare ingots, film ingots, casing ingots, granules and creams, among others. The Company is also engaged in the manufacture, processing and trading of medical equipment. The Company distributes its products within the domestic market and to overseas markets.